Gilead Sciences, Inc. $GILD Stock Purchased by Rakuten Investment Management Inc.

Rakuten Investment Management Inc. lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 10.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 330,225 shares of the biopharmaceutical company’s stock after purchasing an additional 31,109 shares during the quarter. Rakuten Investment Management Inc.’s holdings in Gilead Sciences were worth $49,956,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Provenance Wealth Advisors LLC increased its holdings in shares of Gilead Sciences by 412.3% during the 3rd quarter. Provenance Wealth Advisors LLC now owns 13,418 shares of the biopharmaceutical company’s stock worth $2,000,000 after buying an additional 10,799 shares during the last quarter. Hughes Financial Services LLC raised its position in shares of Gilead Sciences by 72.7% during the 3rd quarter. Hughes Financial Services LLC now owns 221 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 93 shares during the period. Associated Banc Corp purchased a new stake in shares of Gilead Sciences during the 3rd quarter valued at approximately $216,000. Integrity Alliance LLC. lifted its holdings in Gilead Sciences by 9.6% in the third quarter. Integrity Alliance LLC. now owns 5,080 shares of the biopharmaceutical company’s stock valued at $757,000 after acquiring an additional 445 shares during the last quarter. Finally, Integrity Advisory Solutions LLC acquired a new position in Gilead Sciences in the third quarter valued at approximately $207,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Bank of America increased their price objective on Gilead Sciences from $168.00 to $172.00 and gave the stock a “buy” rating in a research report on Tuesday, October 20th. Citigroup lifted their target price on Gilead Sciences from $165.00 to $188.00 and gave the company a “buy” rating in a research report on Friday, October 30th. Wall Street Zen raised Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, September 19th. Barclays lowered their price target on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a report on Wednesday, July 29th. Finally, HSBC increased their price target on Gilead Sciences from $155.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. Twenty-three research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $170.15.

Insider Buying and Selling

In other news, Director Anthony Welters sold 18,000 shares of the stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $148.62, for a total transaction of $2,675,160.00. Following the sale, the director owned 12,894 shares of the company’s stock, valued at approximately $1,916,306.28. This represents a 58.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total transaction of $468,660.00. Following the completion of the transaction, the chief financial officer directly owned 161,096 shares of the company’s stock, valued at approximately $25,166,417.12. The trade was a 1.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 126,881 shares of company stock worth $19,252,455 over the last 90 days. 0.30% of the stock is owned by insiders.

Gilead Sciences Trading Down 1.7%

GILD opened at $167.47 on Wednesday. Gilead Sciences, Inc. has a 52 week low of $116.88 and a 52 week high of $175.65. The business has a fifty day simple moving average of $151.77 and a 200-day simple moving average of $140.25. The firm has a market cap of $207.72 billion, a P/E ratio of -53.00 and a beta of 0.35. The company has a quick ratio of 0.95, a current ratio of 1.38 and a debt-to-equity ratio of 1.84.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, beating analysts’ consensus estimates of $2.19 by $0.36. The business had revenue of $8.30 billion during the quarter, compared to analysts’ expectations of $7.81 billion. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The company’s revenue was up 6.8% on a year-over-year basis. During the same period in the previous year, the firm posted $2.47 earnings per share. On average, equities analysts expect that Gilead Sciences, Inc. will post -1.03 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is -103.80%.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Analysts remain broadly upbeat, with several recent price-target increases, including targets as high as $200. Coverage cites Gilead’s recent execution, HIV franchise and pipeline; a separate estimate of fair value also moved higher. Gilead price target raised to $200 Gilead fair-value estimate
• Positive Sentiment: Gilead plans to present results from more than 50 studies, including late-breaking clinical data and real-world evidence, at HIV Glasgow 2026 on November 8–11. The updates could offer pipeline and franchise catalysts. Gilead HIV Glasgow presentation
• Positive Sentiment: BioNTech said it advanced a planned Phase 3 trial, pending regulatory approval, combining its candidate pumitamig with Gilead’s cancer drug Trodelvy in triple-negative breast cancer. This represents potential progress for Gilead’s oncology collaboration, though the study remains subject to approval. BioNTech quarterly results and update
• Negative Sentiment: Investors bought 16,499 GILD put options, about 107% above typical volume. The jump may signal increased hedging or bearish positioning, although options activity alone does not establish a market view.
• Negative Sentiment: CEO Daniel O’Day sold a combined 30,881 shares in two recent transactions. Both sales were made under a prearranged Rule 10b5-1 plan, which may temper their significance, but insider selling can still be viewed cautiously by investors. CEO share sale details

Gilead Sciences Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.